These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 35986484)

  • 1. SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2.
    de Michelena P; Olea B; Torres I; González-Candelas F; Navarro D
    J Med Virol; 2022 Dec; 94(12):5836-5840. PubMed ID: 35986484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants.
    de Michelena P; Torres I; Ferrando EC; Olea B; González-Candelas F; Sánchez G; Navarro D
    Clin Microbiol Infect; 2023 Feb; 29(2):256.e1-256.e4. PubMed ID: 36115649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults.
    Costa R; Bueno F; Albert E; Torres I; Carbonell-Sahuquillo S; Barrés-Fernández A; Sánchez D; Padrón C; Colomina J; Lázaro Carreño MI; Bretón-Martínez JR; Martínez-Costa C; Navarro D
    Clin Microbiol Infect; 2021 Dec; 27(12):1858.e1-1858.e7. PubMed ID: 34384874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
    Torres I; Bellido-Blasco JB; Gimeno C; Burgos JS; Albert E; Moya-Malo R; Gascó-Laborda JC; Tornero A; Soriano J; Meseguer-Ferrer N; Martínez-Serrano M; Ortíz-Rambla J; Buj H; Hernández N; Peiró S; Salas D; Limón R; Vanaclocha H; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Navarro D;
    J Med Virol; 2022 Aug; 94(8):3776-3782. PubMed ID: 35445415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant.
    Migueres M; Dimeglio C; Mansuy JM; Abravanel F; Raymond S; Latour J; Jeanne N; Ranger N; Lhomme S; Saune K; Tremeaux P; Izopet J
    Clin Infect Dis; 2023 Feb; 76(3):e514-e517. PubMed ID: 35796540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant.
    Sentis C; Billaud G; Bal A; Frobert E; Bouscambert M; Destras G; Josset L; Lina B; Morfin F; Gaymard A; The Covid-Diagnosis Hcl Study Group
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study.
    Colaneri M; Matone M; Fassio F; Lai A; Bergna A; Ventura CD; Galli L; Scaglione G; Gori A; Schiavini M
    Diagn Microbiol Infect Dis; 2024 Oct; 110(2):116452. PubMed ID: 39032318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.
    Scutari R; Fox V; De Ioris MA; Fini V; Granaglia A; Costabile V; Colagrossi L; Russo C; Mastronuzzi A; Locatelli F; Perno CF; Alteri C
    BMC Infect Dis; 2023 Mar; 23(1):133. PubMed ID: 36882724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA.4 and -BA.5.
    Krenn F; Dächert C; Badell I; Lupoli G; Öztan GN; Feng T; Schneider N; Huber M; Both H; Späth PM; Muenchhoff M; Graf A; Krebs S; Blum H; Durner J; Czibere L; Kaderali L; Keppler OT; Baldauf HM; Osterman A
    Med Microbiol Immunol; 2023 Oct; 212(5):323-337. PubMed ID: 37561225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
    Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity.
    Yuasa S; Nakajima J; Takatsuki Y; Takahashi Y; Tani-Sassa C; Iwasaki Y; Nagano K; Sonobe K; Yoshimoto T; Nukui Y; Takeuchi H; Tanimoto K; Tanaka Y; Kimura A; Ichimura N; Tohda S
    J Med Virol; 2022 Nov; 94(11):5543-5546. PubMed ID: 35790476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.